Cryo-Cell International vs NewGenIvf
CCEL and NIVF side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CCEL and NIVF compare
NewGenIvf grew revenue faster over the last twelve months (336% versus −2.0% for Cryo-Cell International).
NewGenIvf keeps more of each dollar of sales as profit, with a net margin of 41.7% compared with −6.2% at Cryo-Cell International.
NewGenIvf scores higher on the StockData Score (7 against 2 for Cryo-Cell International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CCEL | NIVF |
|---|---|---|
| Size and price | ||
| Market cap | $39.1M | – |
| Share price | $4.85 | $0.231 |
| Change, 1 year | 19.8% | −100.0% |
| Change, 5 years | −60.4% | – |
| Beta (5Y) | 0.26 | 2.87 |
| Employees | 72 | 87 |
| StockData Score | ||
| Total score | 2 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× | – |
| EV/EBITDA | 41.0× | – |
| P/FCF | 8.4× | – |
| FCF yield | 11.9% | – |
| Growth | ||
| Revenue growth (TTM) | −2.0% | 336% (better) |
| Revenue growth, 5Y average | 0.27% | – |
| Profitability | ||
| Gross margin | 78.5% (better) | 4.0% |
| Operating margin | 0.61% (better) | −45.2% |
| Net margin | −6.2% | 41.7% (better) |
| FCF margin | 14.9% (better) | −46.7% |
| Return on equity | – | 77.9% |
| Return on invested capital | – | −70.9% |
| Financial health | ||
| Net debt / EBITDA | 3.65 | – |
| Interest coverage | 0.1× (better) | −17.4× |
| Current ratio | 0.86 | 1.06 (better) |
| Altman Z-score | −0.06 | – |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 6.9% | – |
| Held by insiders | 41.7% | – |
| Insider net buying, 12 months | – | $4.2M |
| Short interest, % of float | 0.26% | – |
Go deeper
- CCEL stock overview
- CCEL income statement
- CCEL valuation and score
- NIVF stock overview
- NIVF income statement
- NIVF valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.